The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Atrovent Inhalation Solution? Atrovent Inhalation ...

Inhalation: The recommended dose (ipratropium bromide nasal spray 0.03%) is two sprays (42 mcg) per nostril two or three times daily (total dose 168 to 252 mcg/day).

Overview: Nasal ipratropium is used to help reduce symptoms of a runny nose. It works by reducing the amount of liquid and mucus made in your nose. Common side effects can include dryness of the nose, ...

Learn everything you need to know about Ipratropium Bromide-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...

Background: Studies have suggested an increased risk of cardiovascular morbidity and mortality associated with the use of ipratropium bromide. We sought to examine the association between ipratropium ...

Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...

Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

Pharma major Lupin Ltd on Friday said it has launched Ipratropium Bromide nasal spray, used in treatment of runny nose, in the US market. The Ipratropium Bromide nasal solution (nasal spray) launched ...

The FDA has advised consumers not to use albuterol sulfate inhalation solution, 0.083%, and ipratropium bromide inhalation solutions, 0.02%, unit-dose vials, purchased after September 8, 2009 and ...

RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...